DNA Vaccines against Protozoan Parasites: Advances and Challenges

Over the past 15 years, DNA vaccines have gone from a scientific curiosity to one of the most dynamic research field and may offer new alternatives for the control of parasitic diseases such as leishmaniasis and Chagas disease. We review here some of the advances and challenges for the development of DNA vaccines against these diseases. Many studies have validated the concept of using DNA vaccines for both protection and therapy against these protozoan parasites in a variety of mouse models. The challenge now is to translate what has been achieved in these models into veterinary or human vaccines of comparable efficacy. Also, genome-mining and new antigen discovery strategies may provide new tools for a more rational search of novel vaccine candidates.

• Publication year

  2007

• Venue

  Journal of Biomedicine and Biotechnology

• Publication date

  2007-06-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2007/90520PMID 17710244PMCID 1940056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RNAi-mediated chromatin silencing in fission yeast.

  2008cited by this paper
• Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice.

  2007cited by this paper
• DNA Vaccines: Recent Developments and Future Possibilities

  2006influential reference
• Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts.

  2006cited by this paper
• Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

  2006cited by this paper
• Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.

  2006influential reference
• Immunological and pathological responses in BALB/c mice induced by genetic administration of Tc13 Tul antigen of Trypanosoma cruzi

  2006cited by this paper
• Heterologous Priming-Boosting with DNA and Modified Vaccinia Virus Ankara Expressing Tryparedoxin Peroxidase Promotes Long-Term Memory against Leishmania major in Susceptible BALB/c Mice

  2006cited by this paper
• A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus

  2006cited by this paper
• Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity

  2006cited by this paper
• Distinct Kinetics of Effector CD8+ Cytotoxic T Cells after Infection with Trypanosoma cruzi in Naïve or Vaccinated Mice

  2006cited by this paper
• Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.

  2006cited by this paper
• MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.

  2006cited by this paper
• Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.

  2006cited by this paper
• From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.

  2006cited by this paper
• The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.

  2006cited by this paper
• Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.

  2006cited by this paper
• Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice.

  2006cited by this paper
• Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis)

  2006cited by this paper
• Comparative salivary gland transcriptomics of sandfly vectors of visceral leishmaniasis

  2006cited by this paper
• Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection against Both Pentavalent Antimonial-Sensitive and -Resistant Strains of Leishmania donovani That Correlates with Inducible Nitric Oxide Synthase Activity and IL-4 Generation: Evidence for Mixed Th1- and Th2-Like Responses

  2005cited by this paper
• Evidence of Positive Darwinian Selection in Putative Meningococcal Vaccine Antigens

  2005cited by this paper
• T helper (h)1/Th2 and Leishmania: paradox rather than paradigm.

  2005cited by this paper
• Current status and future prospects for a vaccine against American trypanosomiasis

  2005cited by this paper
• Heterologous Prime-Boost Vaccination with the LACK Antigen Protects against Murine Visceral Leishmaniasis

  2005cited by this paper
• Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge

  2005cited by this paper
• Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana.

  2005cited by this paper
• Are Extensive T Cell Epitope Polymorphisms in the Plasmodium falciparum Circumsporozoite Antigen, a Leading Sporozoite Vaccine Candidate, Selected by Immune Pressure?1

  2005cited by this paper
• The Genome of the Kinetoplastid Parasite, Leishmania major

  2005cited by this paper
• Advances in leishmaniasis.

  2005cited by this paper
• A role for IgG immune complexes during infection with the intracellular pathogen Leishmania

  2005cited by this paper
• Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

  2005cited by this paper
• Genetic variation in the sand fly salivary protein, SP‐15, a potential vaccine candidate against Leishmania major

  2005cited by this paper
• Trypanosoma cruzi-induced molecular mimicry and Chagas' disease.

  2005cited by this paper
• Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana.

  2005cited by this paper
• Cross-Protective Efficacy of a Prophylactic Leishmania donovani DNA Vaccine against Visceral and Cutaneous Murine Leishmaniasis

  2005cited by this paper
• Where do we stand on the autoimmunity hypothesis of Chagas disease?

  2005cited by this paper
• Therapeutic Vaccines for Chronic Infections

  2004cited by this paper
• Antigenic diversity in maxadilan, a salivary protein from the sand fly vector of American visceral leishmaniasis.

  2004cited by this paper
• From genomes to vaccines for leishmaniasis.

  2004cited by this paper
• A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.

  2004cited by this paper
• Utility of the Trypanosoma cruzi Sequence Database for Identification of Potential Vaccine Candidates by In Silico and In Vitro Screening

  2004cited by this paper
• Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice

  2004cited by this paper
• Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACK

  2004cited by this paper
• Approaches to Enhance the Efficacy of DNA Vaccines

  2004cited by this paper
• Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.

  2004cited by this paper
• Protective Immunity Against Trypanosoma cruzi Infection in a Highly Susceptible Mouse Strain After Vaccination with Genes Encoding the Amastigote Surface Protein-2 and Trans-Sialidase

  2004cited by this paper
• Identification of the most abundant secreted proteins from the salivary glands of the sand fly Lutzomyia longipalpis, vector of Leishmania chagasi

  2004cited by this paper
• Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?

  2004cited by this paper
• Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection

  2004cited by this paper
• Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK.

  2003cited by this paper
• A DNA‐priming protein‐boosting regimen significantly improves type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain

  2003cited by this paper
• Infection with Dna Vaccines in Mice

  2003cited by this paper
• Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines.

  2003cited by this paper
• Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses

  2003cited by this paper
• The Leishmania infantum Acidic Ribosomal Protein P0 Administered as a DNA Vaccine Confers Protective Immunity to Leishmania major Infection in BALB/c Mice

  2003cited by this paper
• DNA Immunization with the Gene Encoding P4 Nuclease of Leishmania amazonensis Protects Mice against Cutaneous Leishmaniasis

  2003cited by this paper
• DNA vaccines induce partial protection against Leishmania mexicana.

  2003cited by this paper
• Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection.

  2003influential reference
• Immunization with cDNA Expressed by Amastigotes of Trypanosoma cruzi Elicits Protective Immune Response against Experimental Infection

  2003cited by this paper
• Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.

  2003cited by this paper
• Activation of Natural Killer T Cells by -Galactosylceramide Impairs DNA Vaccine-Induced Protective Immunity against Trypanosoma cruzi

  2003cited by this paper
• The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.

  2003cited by this paper
• Vaccination with Plasmid DNA Encoding TSA/LmSTI1 Leishmanial Fusion Proteins Confers Protection against Leishmania major Infection in Susceptible BALB/c Mice

  2002cited by this paper
• A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

  2002cited by this paper
• Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine.

  2002cited by this paper
• Coadministration of an Interleukin-12 Gene and a Trypanosoma cruzi Gene Improves Vaccine Efficacy

  2002cited by this paper
• Genetic Immunization Elicits Antigen-Specific Protective Immune Responses and Decreases Disease Severity in Trypanosoma cruzi Infection

  2002influential reference
• Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.

  2002cited by this paper
• Optimization of DNA vaccination against cutaneous leishmaniasis.

  2002cited by this paper
• DNA Immunization with Trypanosoma cruzi HSP70 Fused to the KMP11 Protein Elicits a Cytotoxic and Humoral Immune Response against the Antigen and Leads to Protection

  2001cited by this paper
• Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis

  2001cited by this paper
• Parasite persistence in the aetiology of Chagas disease.

  2001cited by this paper
• A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.

  2001cited by this paper
• Sandfly Maxadilan Exacerbates Infection with Leishmania major and Vaccinating Against It Protects Against L. major Infection1

  2001cited by this paper
• Gp63 gene polymorphism and population structure of Leishmania donovani complex: influence of the host selection pressure?

  2001cited by this paper
• DNA Sequences Encoding CD4+ and CD8+T-Cell Epitopes Are Important for Efficient Protective Immunity Induced by DNA Vaccination with a Trypanosoma cruziGene

  2001cited by this paper
• Toward a Defined Anti-Leishmania Vaccine Targeting Vector Antigens

  2001cited by this paper
• The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge

  2001cited by this paper
• Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters.

  2001cited by this paper
• Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana.

  2000cited by this paper
• Identification of Vaccine Candidates for Experimental Visceral Leishmaniasis by Immunization with Sequential Fractions of a cDNA Expression Library

  2000cited by this paper
• Nonrandom spatial distribution of synonymous substitutions in the GP63 gene from Leishmania.

  2000cited by this paper
• Parasite candidate vaccines: a warning from polymorphic Leishmania populations.

  2000cited by this paper
• Involvement of CD4+ Th1 Cells in Systemic Immunity Protective against Primary and Secondary Challenges withTrypanosoma cruzi

  2000cited by this paper
• Requirements for the Maintenance of Th1 Immunity In Vivo Following DNA Vaccination: A Potential Immunoregulatory Role for CD8+ T Cells

  2000cited by this paper
• Therapy of murine cutaneous leishmaniasis by DNA vaccination.

  2000cited by this paper
• The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.

  2000cited by this paper
• Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies.

  2000cited by this paper
• DNA-Based Immunization with Trypanosoma cruzi Complement Regulatory Protein Elicits Complement Lytic Antibodies and Confers Protection against Trypanosoma cruzi Infection

  2000cited by this paper
• Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.

  1999cited by this paper
• Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection.

  1999cited by this paper
• Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein

  1999cited by this paper
• Predominance of CD4 Th1 and CD8 Tc1 Cells Revealed by Characterization of the Cellular Immune Response Generated by Immunization with a DNA Vaccine Containing a Trypanosoma cruzi Gene

  1999cited by this paper
• Development of a Natural Model of Cutaneous Leishmaniasis: Powerful Effects of  Vector Saliva and Saliva Preexposure on the Long-Term Outcome of Leishmania major Infection in the Mouse Ear Dermis

  1998cited by this paper
• Genetic Immunization with Glycoprotein 63 cDNA Results in a Helper T Cell Type 1 Immune Response and Protection in a Murine Model of Leishmaniasis

  1998cited by this paper
• Regulation of protective immunity against Leishmania major in mice.

  1998cited by this paper
• Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.

  1998cited by this paper
• Vaccination with Trypomastigote Surface Antigen 1-Encoding Plasmid DNA Confers Protection against Lethal Trypanosoma cruzi Infection

  1998cited by this paper
• The immune response to Leishmania: mechanisms of parasite control and evasion.

  1998cited by this paper

• Introduction of protein vaccine candidate based on AP65, AP33, and α-actinin proteins against Trichomonas vaginalis parasite: an immunoinformatics design

  2024cites this paper
• Review of Molecular Approaches in Leishmaniasis Vaccines: Implications and Restrictions

  2022cites this paper
• REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII

  2021influential citation
• Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease

  2021cites this paper
• Oxidative stress implications for therapeutic vaccine development against Chagas disease

  2021cites this paper
• Immunoinformatics based design and prediction of proteome-wide killer cell epitopes of Leishmania donovani: Potential application in vaccine development

  2021cites this paper
• Targeting DNA topoisomerases in parasitic protozoa by natural products: Chemical and biological perspectives

  2020cites this paper
• In silico analysis and expression of a new chimeric antigen as a vaccine candidate against cutaneous leishmaniasis

  2020influential citation
• Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease.

  2020cites this paper
• Antigen-Based Nano-Immunotherapy Controls Parasite Persistence, Inflammatory and Oxidative Stress, and Cardiac Fibrosis, the Hallmarks of Chronic Chagas Cardiomyopathy, in A Mouse Model of Trypanosoma cruzi Infection

  2020cites this paper
• DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi

  2020cites this paper
• Dose effects of a DNA vaccine encoding immobilization antigen on immune response of channel catfish against Ichthyophthirius multifiliis.

  2020cites this paper
• Alterations to the cardiac metabolome induced by chronic T. cruzi infection relate to the degree of cardiac pathology

  2020cites this paper
• TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization

  2019cites this paper
• Immunity and vaccine development efforts against Trypanosoma cruzi.

  2019cites this paper
• Bioinformatics analysis of single and multi-hybrid epitopes of GRA-1, GRA-4, GRA-6 and GRA-7 proteins to improve DNA vaccine design against Toxoplasma gondii

  2018cites this paper
• Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from Leishmania major and Phlebotomus papatasi against Cutaneous Leishmaniasis.

  2018cites this paper
• Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype

  2017cites this paper
• Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis

  2017cites this paper
• Cutaneous Leishmaniasis: Update on Vaccine Development

  2017cites this paper
• Avaliação do processo de imunização de murganhos vacinados com virus-like particles (VLPs) contendo candidatos antigénicos de Trypanosoma cruzi

  2017cites this paper
• Immunogenicity Prediction by VaxiJen: A Ten Year Overview

  2017cites this paper
• Safety, immunogenicity, and cross-species protection of a plasmid DNA encoding Plasmodium falciparum SERA5 polypeptide, microbial epitopes and chemokine genes in mice and olive baboons

  2017cites this paper
• The Driving of Immune Response by Th1 Adjuvants in Immunization of Mice with Trypanosoma cruzi marinkellei Elicits a Controversial Infection Control

  2016cites this paper
• Possibilities and challenges for developing a successful vaccine for leishmaniasis

  2016cites this paper
• Mammalian Parasitic Vaccine: A Consolidated Exposition

  2015cites this paper
• Genome-Wide Prediction of Vaccine Candidates for Leishmania major: An Integrated Approach

  2015cites this paper
• Prophylactic and therapeutic DNA vaccines against Chagas disease

  2015cites this paper
• β-Adrenergic blockade protects BALB/c mice against infection with a small inoculum of Leishmania mexicana mexicana (LV4).

  2015cites this paper
• Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi.

  2013cites this paper
• Development of Leishmania vaccines: predicting the future from past and present experience

  2012cites this paper
• Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.

  2012cites this paper
• Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine

  2012cites this paper
• Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

  2012cites this paper
• Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi.

  2012cites this paper
• The Leishmania TDR1 family-related gene: functional studies and evaluation of TDR1 recombinant protein as a vaccine agaist leishmaniasis

  2012cites this paper
• Evaluation of protection induced by DNA vaccine candidate against Leishmania mexicana in BALB/c mice model

  2012influential citation
• Leishmania Vaccines Updates

  2012cites this paper
• Advances and challenges towards a vaccine against Chagas disease

  2011cites this paper
• Mechanisms of immunity to Leishmania major infection in mice: the contribution of DNA vaccines coding for two novel sets of histones (H2A-H2B or H3-H4).

  2011cites this paper
• Vaccine development against Trypanosoma cruzi and Chagas disease.

  2011cites this paper
• Estudo da imunogenicidade de vacinas de Mycobacterium smegmatis recombinante, expressando o gene que codifica aproteína ácida ribossomal de Leishmania infantum (LiP0), contra a infecção por Leishmania chagasi em hamster

  2011cites this paper
• Cysteine proteases as potential antigens in antiparasitic DNA vaccines.

  2011cites this paper
• Antileishmanial Drugs: search for t SIR2 inhibitors

  2011cites this paper
• Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.

  2010cites this paper
• Vaccination with Recombinant Leishmania donovani Gamma-Glutamylcysteine Synthetase Fusion Protein Protects Against L. donovani Infection

  2010cites this paper
• The Potential Economic Value of a Trypanosoma cruzi (Chagas Disease) Vaccine in Latin America

  2010influential citation
• GPIomics: global analysis of glycosylphosphatidylinositol-anchored molecules of Trypanosoma cruzi

  2009cites this paper
• Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.

  2009cites this paper
• Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era.

  2009cites this paper
• Mining the Leishmania genome for novel antigens and vaccine candidates

  2009cites this paper
• A combination DNA vaccine encoding nucleoside hydrolase 36 and glycoproteine 63 protects female but not male hamsters against Leishmania mexicana.

  2009cites this paper
• Chapter 69 – American Trypanosomiasis

  2009cites this paper
• Immunopathology of natural infection with Trypanosoma cruzi in dogs.

  2009cites this paper
• Vaccination approaches against Trypanosoma cruzi

  2009cites this paper
• Vacinação com a proteína 2 da superfície de amastigotas contra a infecção experimental pelo Trypanosoma cruzi: eficácia de diferentes estratégias vacinais e mecanismos de imunidade

  2009cites this paper
• Bringing DNA vaccines closer to commercial use.

  2009cites this paper
• DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.

  2009cites this paper
• Vaccination approaches against Trypanosoma cruzi infection

  2009cites this paper
• A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis

  2009cites this paper
• Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage

  2009cites this paper
• Vaccines under study: non‐HIV vaccines

  2009cites this paper
• Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.

  2008cites this paper
• Novel Protective Antigens Expressed by Trypanosoma cruzi Amastigotes Provide Immunity to Mice Highly Susceptible to Chagas' Disease

  2008cites this paper
• Absence of experimental cross-protection induced by a Trypanosoma cruzi-like strain isolated from bats.

  2008cites this paper
• Therapeutic DNA Vaccine against Trypanosoma cruzi Infection in Dogs

  2008cites this paper